Tivanisiran

N/A

Report date: 2026/03/09 20:02:04

Base Information

Drug NameTivanisiran
Drug Alias NameSYL-1001SYL-1001-DP
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionVanilloid receptor antagonistsRNA interference
TargetsTransient receptor potential cation channel subfamily V member 1
Therapy Area/IndicationsSjogren-Larsson SyndromeDry Eye SyndromesEye Pain +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSlovakiaPortugal +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSylentis Sa
China Registration ClassN/A

Develop Information

Active CompaniesSylentis Sa
Inactive CompaniesN/A
Active IndicationsSjogren-Larsson SyndromeDry Eye Syndromes
Inactive IndicationsEye PainXerophthalmia

Other Information

ATC CodeN/A
Related LinksN/A